SRX251
SRX251, or SRX-251, also known as API-251, is a selective vasopressin V1A receptor antagonist that is or was under development for the treatment of aggression. It was also being developed for the treatment of dysmenorrhea, but development for this indication was discontinued. The drug is taken by mouth. SRX251 reduces aggressive behavior in rodents. It is or was being developed by Azevan Pharmaceuticals. In 2007, it was in phase 1 clinical trials.